Trican Biotechnology collaborates on cancer diagnostics research
NEWS PROVIDED BY
New Taipei City, Taiwan
November 17th, 2026
New Taipei City, Taiwan – Nov, 17, 2026 - Trican Biotechnology (“Trican”), today announced it is advancing collaborative research with Mayo Clinic for novel cancer diagnostics using antibodies from Trican.
Monoclonal antibodies targeting a specific protein in cancer recurrence and treatment resistance are jointly under investigation. Mayo Clinic will lead the development and validation of antibody-based diagnostics with clinical samples. Trican will support the design and generation of such monoclonal antibody that could integrate into detection platforms.
“We are pleased to enter into a research collaboration with Mayo Clinic with its outstanding clinical research unit for cancer diagnostics,” said Sharon Wang, GM of Trican. “This agreement combines the speed and quality from our antibody discovery with clinical medicine for the future of precision oncology.”
About Trican Biotechnology.
Trican Biotechnology drives multimodal SERAbodies (Sequentially Enriched Recombinant Antibodies) discovery from deep diversity, somatically hypermutated specificity, and engineered developability. Trican is actively seeking partners worldwide to address unmet medical needs.
